Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$1.81 USD
-0.13 (-6.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Verrica Pharmaceuticals Inc. [VRCA]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
1Q24: YCANTH Uptake Ahead of Projections; Raise PT to $14; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
4Q23: YCANTH Beats in First Full Quarter; We Raise Year-One Sales, Margins, and Our Target to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
3Q23: Solid YCANTH Early Launch Indicators; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
KOLs Bolster View on Strong YCANTH Prospects; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Post-Approval Pullback Overdone; YCANTH Should Be Differentiated Derm Launch; Reiterate Buy; Raise Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Expect Final Approval, Finally, End of This Week; Launch by September; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 NDA Resubmitted; Expect Approval by July; Reiterate But
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
3Q22: VP-102 On Track for 1Q23 NDA Resubmission; Could Put Launch Slightly Ahead of Our Projections; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
2Q22: Moving Quickly With Alternate Supplier to Potentially File VP-102 in 1Q23; Tweak PT to $11 Post Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
FDA Meeting Suggests Potential Expedited NDA Resubmission With Alternate API Manufacturer
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Third Party Quality Issues Strike Again; Still See Ultimate Approval and Potential But Push Out 18 Mths; PT Down to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 Homestretch (Hopefully) With May 24 PDUFA Date; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 NDA Resubmitted; If Qualifies as Class I Review, Potential January 24 PDUFA Date; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Supplier VAI Status Hopefully Clears Way for VP-102 Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Supplier 483s Trigger Surprise CRL; Management Aims for Expedited Resolution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
PDUFA Push to September Doesn?t Dampen Our Approval Confidence; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Expect June 23 VP-102 Molluscum Approval and Late-Summer Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
June PDUFA Nearing; Japan Partner Opt-In is Encouraging Read-Through
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
YCANTH NDA Resubmitted Ahead of Schedule; We See High Probability of Mid-21 Approval; Reiterate Buy and Raise to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O